INS and type 2 diabetes mellitus: In the ELLIPSE trial, 135 adolescents with T2DM between the ages of 10 and 16 years (mean age 14.6 years) who had glycated hemoglobin levels between 7 and 11% if they were being treated with diet or exercise alone or between 6.5 and 11% if they were being treated with metformin with or without insulin were randomized to subcutaneous liraglutide (up to 1.8 mg daily) or placebo for 26 weeks plus metformin with or without basal insulin in combination with diet and exercise regimen [40].